Do you consider ttmt successful? Question Christeen et al. asked to 100+ PsA pts. 1/3 pts said no, they had > TJC, > SJC, > Pso & > dactylitis. Failure also w/: pain 24%, pso 15%, fatigue 12% and < ability to be active 9%. https://t.co/dQseCNSDBS Abstr #0393 #ACR22 @Rheumnow https://t.co/kGlmscsKL7

• Are We Meeting Patients&#039; Treatment Goals with Guideline-Based Therapy for …

MACE and VTE from 9 (6 RA, 2 PsA, 1 AS) RCTs w/ UPA. 6000+ pts received UPA 40-50% w/ > or = 2 BL CV risk factors. 41 MACE UPA 15mg RA-PsA group & 2 fatal VTE UPA 15mg RA group. Overlapping confidence intervals w/ADA & MTX. https://t.co/7xtZlDIkVu Abs#0510 #ACR22 @Rheumnow https://t.co/reywXk5Z0Z

• MACE and VTE Across Upadacitinib Clinical Trial Programs in Rheumatoid Arthriti…

RECITAL trial comparing ritux vs cyclo for CTD-ILD. This is a sub-group analysis of larger trial. 1/n @RheumNow #ACR22 #Plenary

GPA is a rare cause of both submandibular gland enlargement and dacryoadenitis. Can look like IgG4RD and Sjogrens. @RheumNow #ACR22 #Pearls https://t.co/Gw6OF4H2w2

Are my patients represented in PsA trials? @RheumNow #ACR22 Abstract #0090; Ignite Talk ☝️Of 25 RCT from 2002-2022, only 13 included patients of non-White race ☝️Hispanic/Latinx ethnicity was reported in 0 studies ☝️Black individuals represented < 1% patients included

Dr. John Stone pronounces GiACTA “GEE-ACTA”. I have been pronouncing it “GIA-ACTA” and will now correct myself #vasculitis #ACR22

#ACR22 Year in Review. Dr Langford summarised significant progress attained in 2022 in combating #COVID and protect our immunosuppressed patients @RheumNow https://t.co/lZSDRj3bkm

Key points in managing MDA5+ DM 1. Monitor lungs - HRCT/PFTs 2. Test muscle endurance (ref: IMACS site) not just strength 3. Close observation 4. MTX/MMF initial treatments 5. Repeat muscle biopsy if diagnosis unclear Meet the Expert Lundberg I, IMM session @RheumNow #ACR22 https://t.co/ZVFsYgDBx2

Key points in managing MDA5+ DM 1. Consider Tofacitinib 5-10mg bd 2. Low to mid dose Prednisolone 20-30mg tapering 3. Other Rx: Tacrolimus, IVIG 4. Poor prognostic factors: lymphopenia, raised ferritin, old age, rapid ILD progression Wang GC, IIM session @RheumNow #ACR22 https://t.co/UF2PjAg0Mw

Therapies for AS and nr-AxSpA are coming together. Both AS and nr-AxSpA present with similar burden of disease. TNFi, IL-17i and JAKi now approved for use in nr-AxSpA. Jose U Scher, SpA Review @RheumNow #ACR22 https://t.co/vcHcd7OyAU

Mimics of Sjogren’s Syndrome @RheumNow #ACR22 https://t.co/nEAXKb6qF0

“The Stone Age did not end because of a shortage of stones. We need new solutions to our problems” Abraham Verghese. Amazing insight into our challenges in clinic today at the #ACR22 opening session @RheumNow

GCA Fast Track clinics are nice - but usually need specialized ultrasound. What if you don't have it? (also, COVID?) @PennRheum implemented *without* ultrasound Excellent outcomes The early referral triage makes all the difference. Knowledge is power ABST0463 #ACR22 @RheumNow https://t.co/rjkVERW559

More details at https://t.co/4U8v7oeUYW Enormously powerful in these times of rheumatology workforce shortage. I would love to see this in Australia and elsewhere - so much to learn. Congratulations to all involved, and thanks @ACRheum and @UCSF for supporting #ACR22

• RAE | Rheumatology Access Expansion

Just published! QR code attached! #ACR22 @RheumNow https://t.co/lMD0mFoT4M